Drug Trial Radar · NCT02891850
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
Last checked: Nov 20, 2026Latest source record: Feb 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
225
Actual
Start
Jan 11, 2017
Primary completion
Jan 29, 2020
Study completion Mar 3, 2020
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Sep 8, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients
Conditions
- Pulmonary Arterial Hypertension
Interventions
Riociguat (Adempas, BAY63-2521)Drug
Film-coated tablets will be used in this study at a dosage of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg. Tablets will be administered orally.The starting dose is 1 mg TID; the intervals between drug intakes should be 6 to 8 hours. The dosage should be increased by 0.5 mg increments in 2 week intervals to 1.5 mg, 2.0 mg, and 2.5 mg TID (maximal total daily dose).
SildenafilDrug
Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
TadalafilDrug
Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Satisfactory Clinical Response at Week 24Time frame: At Week 24
Locations
81 sites in 21 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Sacramento, California
Site not named
Orlando, Florida
Site not named
Weston, Florida
Site not named
Kansas City, Kansas
Site not named
Louisville, Kentucky
Site not named
Detroit, Michigan
Site not named
Troy, Michigan
Site not named
Newark, New Jersey
Site not named
Mineola, New York
Site not named
New York, New York
Site not named
Rochester, New York
Site not named
Cleveland, Ohio
Site not named
Nashville, Tennessee
Site not named
Dallas, Texas
Site not named
Richmond, Virginia
Site not named
Graz, Austria
Site not named
Leuven, Belgium
Site not named
São Paulo, Brazil
Site not named
São Paulo, Brazil
Site not named
Belo Horizonte, Minas Gerais, Brazil
Site not named
Belo Horizonte, Minas Gerais, Brazil
Site not named
Porto Alegre, Rio Grande do Sul, Brazil
Site not named
Blumenal, Santa Catarina, Brazil
Site not named
Montreal, Quebec, Canada
Site not named
Prague, Czechia
Site not named
Prague, Czechia
Site not named
Aarhus N, Denmark
Site not named
Le Kremlin-Bicêtre, France
Site not named
Rouen, France
Site not named
Berlin, Germany
Site not named
Giessen, Germany
Site not named
Hamburg, Germany
Site not named
Heidelberg, Baden-Wurttemberg, Germany
Site not named
München, Bavaria, Germany
Site not named
München, Bavaria, Germany
Site not named
Würzburg, Bavaria, Germany
Site not named
Hanover, Lower Saxony, Germany
Site not named
Cologne, North Rhine-Westphalia, Germany
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.